Daily Stock Analysis, KMDA, Kamada Ltd, priceseries

Kamada Ltd. Daily Stock Analysis
Stock Information
Open
7.45
Close
7.38
High
7.50
Low
7.35
Previous Close
7.34
Daily Price Gain
0.04
YTD High
8.00
YTD High Date
Nov 25, 2019
YTD Low
4.91
YTD Low Date
Oct 16, 2019
YTD Price Change
2.26
YTD Gain
44.14%
52 Week High
8.00
52 Week High Date
Nov 25, 2019
52 Week Low
4.63
52 Week Low Date
Dec 14, 2018
52 Week Price Change
2.29
52 Week Gain
44.85%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 30. 2017
6.10
Feb 27. 2017
7.04
19 Trading Days
15.48%
Link
LONG
Dec 27. 2017
4.60
Jan 30. 2018
5.55
22 Trading Days
20.67%
Link
LONG
Jul 11. 2018
5.35
Jul 30. 2018
5.65
13 Trading Days
5.68%
Link
LONG
Dec 31. 2018
5.00
Jan 22. 2019
5.28
14 Trading Days
5.60%
Link
Company Information
Stock Symbol
KMDA
Exchange
NasdaqGS
Company URL
http://www.kamada.com
Company Phone
97289406472
CEO
Amir London
Headquarters
-
Business Address
2 HOLTZMAN ST., SCIENCE PARK, REHOVOT, ISRAEL 7670402
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001567529
About

Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment develops, manufactures and sells plasma-derived therapeutics products. The Distribution segment supplies plasma based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Ness Ziona, Israel.

Description

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. Its respiratory disease products, including Glassia used in augmentation therapy for patients with emphysema secondary to congenital alpha-1 antitrypsin deficiency; and Bramitob to manage chronic pulmonary infection. The company's immunoglobulin products include KamRAB for prophylaxis against rabies infection; KamRho(D)IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; Snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. In addition, it provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of proper level in the patient's blood plasma. Further, the company offers Heparin Lock Flush to maintain patency of indwelling IV catheter; Human Transferrin for diagnostic assays and cell cultures; and Kamacaine 0.5% used as anesthesia or analgesia for surgery, obstetrical procedures, and diagnostic and therapeutic procedures, as well as spinal anesthesia for surgery. Additionally, it offers coagulation factors, including Factor VIII, Factor IX, and Bupivacaine. The company also develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary disease, graft-versus-host diseases, and transplantations. It has a collaboration partnership with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States and Europe; and distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.